David Wofsy mainly focuses on Internal medicine, Immunology, Antibody, Monoclonal antibody and Autoimmunity. David Wofsy has included themes like Gastroenterology and Endocrinology in his Internal medicine study. His studies in Murine lupus and CD28 are all subfields of Immunology research.
His study explores the link between Antibody and topics such as Antigen that cross with problems in T cell. His Autoimmunity research is within the category of Immune system. His Lupus nephritis research incorporates themes from Cyclophosphamide, Pharmacology and Prednisone.
David Wofsy mainly investigates Immunology, Internal medicine, Lupus nephritis, Immune system and Autoimmunity. Autoimmune disease, Antibody, Monoclonal antibody, Antigen and T cell are the core of his Immunology study. His Internal medicine study combines topics in areas such as Gastroenterology, Placebo and Endocrinology.
His Lupus nephritis study also includes
His primary areas of study are Internal medicine, Lupus nephritis, Immunology, Placebo and Systemic lupus erythematosus. His research in Internal medicine intersects with topics in Anti-nuclear antibody, Gastroenterology and B-cell activating factor. His Lupus nephritis research is multidisciplinary, relying on both CD8, Kidney, Proteinuria, B cell and Nephritis.
Immune system, Autoimmunity and Autoimmune disease are subfields of Immunology in which his conducts study. His biological study spans a wide range of topics, including Atacicept and Pharmacodynamics. His work in Systemic lupus erythematosus addresses subjects such as Clinical trial, which are connected to disciplines such as Randomized controlled trial.
His primary areas of investigation include Internal medicine, Anti-nuclear antibody, Rheumatology, Immunology and Lupus erythematosus. His studies deal with areas such as Gastroenterology and B-cell activating factor as well as Internal medicine. He frequently studies issues relating to Lupus nephritis and Immunology.
In his work, Atacicept, Post-hoc analysis, Randomized controlled trial and Clinical trial is strongly intertwined with Placebo, which is a subfield of Lupus erythematosus. His Autoimmunity research incorporates elements of Acquired immune system, T cell, B cell, CD11c and Immunotherapy. The study incorporates disciplines such as Inflammation, Adoptive cell transfer, Kidney metabolism and Immune system in addition to Autoimmune disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Martin Aringer;Karen Costenbader;David Daikh;Ralph Brinks.
Arthritis & Rheumatism (2019)
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Gerald B. Appel;Gabriel Contreras;Mary Anne Dooley;Ellen M. Ginzler.
Journal of The American Society of Nephrology (2009)
Treatment of murine lupus with CTLA4Ig.
Barbara K. Finck;Peter S. Linsley;David Wofsy.
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.
D Wofsy;W E Seaman.
Journal of Experimental Medicine (1985)
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis
Mary Anne Dooley;David Jayne;Ellen M. Ginzler;David Isenberg.
The New England Journal of Medicine (2011)
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
Kenneth C. Kalunian;John C. Davis;Joan T. Merrill;Mark C. Totoritis.
Arthritis & Rheumatism (2002)
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
Maria Dall'Era;Eliza Chakravarty;Daniel Wallace;Mark Genovese.
Arthritis & Rheumatism (2007)
Professional Medical Associations and Their Relationships With Industry: A Proposal for Controlling Conflict of Interest
David J. Rothman;Walter J. McDonald;Carol D. Berkowitz;Susan C. Chimonas.
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
David Isenberg;Gerald B. Appel;Gabriel Contreras;Mary A. Dooley.
Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells.
J A Ledbetter;P J Martin;C E Spooner;D Wofsy.
Journal of Immunology (1985)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: